Characteristics of long-term survivors with EGFR mutant (EGFRm) metastatic non-small cell lung cancer (mNSCLC)

AbstractIntroductionCharacteristics of long-term survivors in EGFRm NSCLC are not fully understood. This retrospective analysis evaluated a multi-institution cohort of patients with EGFRm NSCLC treated in the pre-osimertinib era and sought to describe characteristics of long-term survivors. MethodsC...

Full description

Saved in:
Bibliographic Details
Published in:JTO clinical and research reports 2024, p.100669-100669
Main Authors: Tompkins, William, MD, Grady, Connor B., MPH, Hwang, Wei-Ting, PhD, Chandrasekhara, Krishna, McCoach, Caroline, MD, Sun, Fangdi, MD, Liu, Geoffrey, MD, Patel, Devalben, MD, Nieva, Jorge, MD, Herrmann, Amanda, MD, Marrone, Kristen, MD, Lam, Vincent K., MD, Velcheti, Vamsi, MD, Liu, Stephen V., MD, Bravo Montenegro, Gabriela Liliana, MD, Patil, Tejas, MD, Weiss, Jared, MD, Miller, Kelsey Leigh, MD, Schwartzman, William, MD, Dowell, Jonathan E., MD, Shaverdashvili, Khvaramze, MD, Villaruz, Liza, MD, Cass, Amanda, PharmD, Iams, Wade, MD, Aisner, Dara, MD, PhD, Aggarwal, Charu, MD, Camidge, D. Ross, MD PhD, Marmarelis, Melina E., MD, Sun, Lova, MD
Format: Article
Language:English
Subjects:
Hematology, Oncology, and Palliative Medicine
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 100669
container_issue
container_start_page 100669
container_title JTO clinical and research reports
container_volume
creator Tompkins, William, MD
Grady, Connor B., MPH
Hwang, Wei-Ting, PhD
Chandrasekhara, Krishna
McCoach, Caroline, MD
Sun, Fangdi, MD
Liu, Geoffrey, MD
Patel, Devalben, MD
Nieva, Jorge, MD
Herrmann, Amanda, MD
Marrone, Kristen, MD
Lam, Vincent K., MD
Velcheti, Vamsi, MD
Liu, Stephen V., MD
Bravo Montenegro, Gabriela Liliana, MD
Patil, Tejas, MD
Weiss, Jared, MD
Miller, Kelsey Leigh, MD
Schwartzman, William, MD
Dowell, Jonathan E., MD
Shaverdashvili, Khvaramze, MD
Villaruz, Liza, MD
Cass, Amanda, PharmD
Iams, Wade, MD
Aisner, Dara, MD, PhD
Aggarwal, Charu, MD
Camidge, D. Ross, MD PhD
Marmarelis, Melina E., MD
Sun, Lova, MD
description AbstractIntroductionCharacteristics of long-term survivors in EGFRm NSCLC are not fully understood. This retrospective analysis evaluated a multi-institution cohort of patients with EGFRm NSCLC treated in the pre-osimertinib era and sought to describe characteristics of long-term survivors. MethodsClinical characteristics and outcomes were abstracted from the electronic medical records of patients with EGFRm mNSCLC who started first-line therapy before 2015. Demographics and comutations were compared between ≥5 year survivors and
doi_str_mv 10.1016/j.jtocrr.2024.100669
format article
fullrecord <record><control><sourceid>elsevier</sourceid><recordid>TN_cdi_elsevier_clinicalkeyesjournals_1_s2_0_S2666364324000390</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S2666364324000390</els_id><sourcerecordid>1_s2_0_S2666364324000390</sourcerecordid><originalsourceid>FETCH-elsevier_clinicalkeyesjournals_1_s2_0_S26663643240003903</originalsourceid><addsrcrecordid>eNqljz9PwzAQxa0KpFbQb8BwYzsktZ1g6MIStXSoGCi7ZVlu6-A_ks8J4tvjSAzsLHf3nt476UfIA6M1o0xs-rrPUadUc8rbYlEhtjOy4EKIqhFtc_PnnpMlYk8p5Y-MPT3zBQndVSWls0kWs9UI8QwuhktVHA84pNGOMSF82XyF3ev-HfyQVciwmoRfgzdZYValCyGGCr1yDrQpww3hAloFbRKs_NupO3bre3J7Vg7N8nffkZf97qM7VKaI0ZoktbPBauU-zbfBPg4plJxkErmk8jSRTCC8LRDNljb_fvADRABjfQ</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Characteristics of long-term survivors with EGFR mutant (EGFRm) metastatic non-small cell lung cancer (mNSCLC)</title><source>ScienceDirect</source><source>Open Access: PubMed Central</source><creator>Tompkins, William, MD ; Grady, Connor B., MPH ; Hwang, Wei-Ting, PhD ; Chandrasekhara, Krishna ; McCoach, Caroline, MD ; Sun, Fangdi, MD ; Liu, Geoffrey, MD ; Patel, Devalben, MD ; Nieva, Jorge, MD ; Herrmann, Amanda, MD ; Marrone, Kristen, MD ; Lam, Vincent K., MD ; Velcheti, Vamsi, MD ; Liu, Stephen V., MD ; Bravo Montenegro, Gabriela Liliana, MD ; Patil, Tejas, MD ; Weiss, Jared, MD ; Miller, Kelsey Leigh, MD ; Schwartzman, William, MD ; Dowell, Jonathan E., MD ; Shaverdashvili, Khvaramze, MD ; Villaruz, Liza, MD ; Cass, Amanda, PharmD ; Iams, Wade, MD ; Aisner, Dara, MD, PhD ; Aggarwal, Charu, MD ; Camidge, D. Ross, MD PhD ; Marmarelis, Melina E., MD ; Sun, Lova, MD</creator><creatorcontrib>Tompkins, William, MD ; Grady, Connor B., MPH ; Hwang, Wei-Ting, PhD ; Chandrasekhara, Krishna ; McCoach, Caroline, MD ; Sun, Fangdi, MD ; Liu, Geoffrey, MD ; Patel, Devalben, MD ; Nieva, Jorge, MD ; Herrmann, Amanda, MD ; Marrone, Kristen, MD ; Lam, Vincent K., MD ; Velcheti, Vamsi, MD ; Liu, Stephen V., MD ; Bravo Montenegro, Gabriela Liliana, MD ; Patil, Tejas, MD ; Weiss, Jared, MD ; Miller, Kelsey Leigh, MD ; Schwartzman, William, MD ; Dowell, Jonathan E., MD ; Shaverdashvili, Khvaramze, MD ; Villaruz, Liza, MD ; Cass, Amanda, PharmD ; Iams, Wade, MD ; Aisner, Dara, MD, PhD ; Aggarwal, Charu, MD ; Camidge, D. Ross, MD PhD ; Marmarelis, Melina E., MD ; Sun, Lova, MD</creatorcontrib><description><![CDATA[AbstractIntroductionCharacteristics of long-term survivors in EGFRm NSCLC are not fully understood. This retrospective analysis evaluated a multi-institution cohort of patients with EGFRm NSCLC treated in the pre-osimertinib era and sought to describe characteristics of long-term survivors. MethodsClinical characteristics and outcomes were abstracted from the electronic medical records of patients with EGFRm mNSCLC who started first-line therapy before 2015. Demographics and comutations were compared between ≥5 year survivors and <5 year survivors. Multivariable Cox PH and logistic regression models were used to evaluate factors associated with survival and the odds of death within 5 years, respectively. Results133 patients were ≥5-year survivors; 127 were <5-year survivors. Burden of pathogenic comutations including TP53 and PIK3CA was similar between ≥5-year survivors and <5-year survivors. Receipt of first-line chemotherapy rather than EGFR-TKI was similar between the groups (22% of <5-year vs 31% of ≥5-year). Baseline brain metastasis and history of smoking were associated with higher odds of death within 5 years (OR=2.16, p=0.029 and OR=1.90, p=0.046, respectively). Among patients without baseline brain metastases, cumulative incidence of brain metastases at 5 years was 42.3%. Both baseline and post-baseline brain metastasis were associated with worse OS compared to no brain metastasis (HR=3.26, p<0.001 and HR=4.99, p<0.001, respectively). ConclusionsWithin patients treated for EGFRm mNSCLC prior to 2015, absence of brain metastasis and nonsmoking status were predictive of 5-year survival. Our findings help to define a subset of patients with EGFRm NSCLC with excellent survival outcomes who may not require intensification of initial therapy.]]></description><identifier>ISSN: 2666-3643</identifier><identifier>EISSN: 2666-3643</identifier><identifier>DOI: 10.1016/j.jtocrr.2024.100669</identifier><language>eng</language><subject>Hematology, Oncology, and Palliative Medicine</subject><ispartof>JTO clinical and research reports, 2024, p.100669-100669</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4010,27897,27898,27899</link.rule.ids></links><search><creatorcontrib>Tompkins, William, MD</creatorcontrib><creatorcontrib>Grady, Connor B., MPH</creatorcontrib><creatorcontrib>Hwang, Wei-Ting, PhD</creatorcontrib><creatorcontrib>Chandrasekhara, Krishna</creatorcontrib><creatorcontrib>McCoach, Caroline, MD</creatorcontrib><creatorcontrib>Sun, Fangdi, MD</creatorcontrib><creatorcontrib>Liu, Geoffrey, MD</creatorcontrib><creatorcontrib>Patel, Devalben, MD</creatorcontrib><creatorcontrib>Nieva, Jorge, MD</creatorcontrib><creatorcontrib>Herrmann, Amanda, MD</creatorcontrib><creatorcontrib>Marrone, Kristen, MD</creatorcontrib><creatorcontrib>Lam, Vincent K., MD</creatorcontrib><creatorcontrib>Velcheti, Vamsi, MD</creatorcontrib><creatorcontrib>Liu, Stephen V., MD</creatorcontrib><creatorcontrib>Bravo Montenegro, Gabriela Liliana, MD</creatorcontrib><creatorcontrib>Patil, Tejas, MD</creatorcontrib><creatorcontrib>Weiss, Jared, MD</creatorcontrib><creatorcontrib>Miller, Kelsey Leigh, MD</creatorcontrib><creatorcontrib>Schwartzman, William, MD</creatorcontrib><creatorcontrib>Dowell, Jonathan E., MD</creatorcontrib><creatorcontrib>Shaverdashvili, Khvaramze, MD</creatorcontrib><creatorcontrib>Villaruz, Liza, MD</creatorcontrib><creatorcontrib>Cass, Amanda, PharmD</creatorcontrib><creatorcontrib>Iams, Wade, MD</creatorcontrib><creatorcontrib>Aisner, Dara, MD, PhD</creatorcontrib><creatorcontrib>Aggarwal, Charu, MD</creatorcontrib><creatorcontrib>Camidge, D. Ross, MD PhD</creatorcontrib><creatorcontrib>Marmarelis, Melina E., MD</creatorcontrib><creatorcontrib>Sun, Lova, MD</creatorcontrib><title>Characteristics of long-term survivors with EGFR mutant (EGFRm) metastatic non-small cell lung cancer (mNSCLC)</title><title>JTO clinical and research reports</title><description><![CDATA[AbstractIntroductionCharacteristics of long-term survivors in EGFRm NSCLC are not fully understood. This retrospective analysis evaluated a multi-institution cohort of patients with EGFRm NSCLC treated in the pre-osimertinib era and sought to describe characteristics of long-term survivors. MethodsClinical characteristics and outcomes were abstracted from the electronic medical records of patients with EGFRm mNSCLC who started first-line therapy before 2015. Demographics and comutations were compared between ≥5 year survivors and <5 year survivors. Multivariable Cox PH and logistic regression models were used to evaluate factors associated with survival and the odds of death within 5 years, respectively. Results133 patients were ≥5-year survivors; 127 were <5-year survivors. Burden of pathogenic comutations including TP53 and PIK3CA was similar between ≥5-year survivors and <5-year survivors. Receipt of first-line chemotherapy rather than EGFR-TKI was similar between the groups (22% of <5-year vs 31% of ≥5-year). Baseline brain metastasis and history of smoking were associated with higher odds of death within 5 years (OR=2.16, p=0.029 and OR=1.90, p=0.046, respectively). Among patients without baseline brain metastases, cumulative incidence of brain metastases at 5 years was 42.3%. Both baseline and post-baseline brain metastasis were associated with worse OS compared to no brain metastasis (HR=3.26, p<0.001 and HR=4.99, p<0.001, respectively). ConclusionsWithin patients treated for EGFRm mNSCLC prior to 2015, absence of brain metastasis and nonsmoking status were predictive of 5-year survival. Our findings help to define a subset of patients with EGFRm NSCLC with excellent survival outcomes who may not require intensification of initial therapy.]]></description><subject>Hematology, Oncology, and Palliative Medicine</subject><issn>2666-3643</issn><issn>2666-3643</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNqljz9PwzAQxa0KpFbQb8BwYzsktZ1g6MIStXSoGCi7ZVlu6-A_ks8J4tvjSAzsLHf3nt476UfIA6M1o0xs-rrPUadUc8rbYlEhtjOy4EKIqhFtc_PnnpMlYk8p5Y-MPT3zBQndVSWls0kWs9UI8QwuhktVHA84pNGOMSF82XyF3ev-HfyQVciwmoRfgzdZYValCyGGCr1yDrQpww3hAloFbRKs_NupO3bre3J7Vg7N8nffkZf97qM7VKaI0ZoktbPBauU-zbfBPg4plJxkErmk8jSRTCC8LRDNljb_fvADRABjfQ</recordid><startdate>2024</startdate><enddate>2024</enddate><creator>Tompkins, William, MD</creator><creator>Grady, Connor B., MPH</creator><creator>Hwang, Wei-Ting, PhD</creator><creator>Chandrasekhara, Krishna</creator><creator>McCoach, Caroline, MD</creator><creator>Sun, Fangdi, MD</creator><creator>Liu, Geoffrey, MD</creator><creator>Patel, Devalben, MD</creator><creator>Nieva, Jorge, MD</creator><creator>Herrmann, Amanda, MD</creator><creator>Marrone, Kristen, MD</creator><creator>Lam, Vincent K., MD</creator><creator>Velcheti, Vamsi, MD</creator><creator>Liu, Stephen V., MD</creator><creator>Bravo Montenegro, Gabriela Liliana, MD</creator><creator>Patil, Tejas, MD</creator><creator>Weiss, Jared, MD</creator><creator>Miller, Kelsey Leigh, MD</creator><creator>Schwartzman, William, MD</creator><creator>Dowell, Jonathan E., MD</creator><creator>Shaverdashvili, Khvaramze, MD</creator><creator>Villaruz, Liza, MD</creator><creator>Cass, Amanda, PharmD</creator><creator>Iams, Wade, MD</creator><creator>Aisner, Dara, MD, PhD</creator><creator>Aggarwal, Charu, MD</creator><creator>Camidge, D. Ross, MD PhD</creator><creator>Marmarelis, Melina E., MD</creator><creator>Sun, Lova, MD</creator><scope/></search><sort><creationdate>2024</creationdate><title>Characteristics of long-term survivors with EGFR mutant (EGFRm) metastatic non-small cell lung cancer (mNSCLC)</title><author>Tompkins, William, MD ; Grady, Connor B., MPH ; Hwang, Wei-Ting, PhD ; Chandrasekhara, Krishna ; McCoach, Caroline, MD ; Sun, Fangdi, MD ; Liu, Geoffrey, MD ; Patel, Devalben, MD ; Nieva, Jorge, MD ; Herrmann, Amanda, MD ; Marrone, Kristen, MD ; Lam, Vincent K., MD ; Velcheti, Vamsi, MD ; Liu, Stephen V., MD ; Bravo Montenegro, Gabriela Liliana, MD ; Patil, Tejas, MD ; Weiss, Jared, MD ; Miller, Kelsey Leigh, MD ; Schwartzman, William, MD ; Dowell, Jonathan E., MD ; Shaverdashvili, Khvaramze, MD ; Villaruz, Liza, MD ; Cass, Amanda, PharmD ; Iams, Wade, MD ; Aisner, Dara, MD, PhD ; Aggarwal, Charu, MD ; Camidge, D. Ross, MD PhD ; Marmarelis, Melina E., MD ; Sun, Lova, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-elsevier_clinicalkeyesjournals_1_s2_0_S26663643240003903</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Hematology, Oncology, and Palliative Medicine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tompkins, William, MD</creatorcontrib><creatorcontrib>Grady, Connor B., MPH</creatorcontrib><creatorcontrib>Hwang, Wei-Ting, PhD</creatorcontrib><creatorcontrib>Chandrasekhara, Krishna</creatorcontrib><creatorcontrib>McCoach, Caroline, MD</creatorcontrib><creatorcontrib>Sun, Fangdi, MD</creatorcontrib><creatorcontrib>Liu, Geoffrey, MD</creatorcontrib><creatorcontrib>Patel, Devalben, MD</creatorcontrib><creatorcontrib>Nieva, Jorge, MD</creatorcontrib><creatorcontrib>Herrmann, Amanda, MD</creatorcontrib><creatorcontrib>Marrone, Kristen, MD</creatorcontrib><creatorcontrib>Lam, Vincent K., MD</creatorcontrib><creatorcontrib>Velcheti, Vamsi, MD</creatorcontrib><creatorcontrib>Liu, Stephen V., MD</creatorcontrib><creatorcontrib>Bravo Montenegro, Gabriela Liliana, MD</creatorcontrib><creatorcontrib>Patil, Tejas, MD</creatorcontrib><creatorcontrib>Weiss, Jared, MD</creatorcontrib><creatorcontrib>Miller, Kelsey Leigh, MD</creatorcontrib><creatorcontrib>Schwartzman, William, MD</creatorcontrib><creatorcontrib>Dowell, Jonathan E., MD</creatorcontrib><creatorcontrib>Shaverdashvili, Khvaramze, MD</creatorcontrib><creatorcontrib>Villaruz, Liza, MD</creatorcontrib><creatorcontrib>Cass, Amanda, PharmD</creatorcontrib><creatorcontrib>Iams, Wade, MD</creatorcontrib><creatorcontrib>Aisner, Dara, MD, PhD</creatorcontrib><creatorcontrib>Aggarwal, Charu, MD</creatorcontrib><creatorcontrib>Camidge, D. Ross, MD PhD</creatorcontrib><creatorcontrib>Marmarelis, Melina E., MD</creatorcontrib><creatorcontrib>Sun, Lova, MD</creatorcontrib><jtitle>JTO clinical and research reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tompkins, William, MD</au><au>Grady, Connor B., MPH</au><au>Hwang, Wei-Ting, PhD</au><au>Chandrasekhara, Krishna</au><au>McCoach, Caroline, MD</au><au>Sun, Fangdi, MD</au><au>Liu, Geoffrey, MD</au><au>Patel, Devalben, MD</au><au>Nieva, Jorge, MD</au><au>Herrmann, Amanda, MD</au><au>Marrone, Kristen, MD</au><au>Lam, Vincent K., MD</au><au>Velcheti, Vamsi, MD</au><au>Liu, Stephen V., MD</au><au>Bravo Montenegro, Gabriela Liliana, MD</au><au>Patil, Tejas, MD</au><au>Weiss, Jared, MD</au><au>Miller, Kelsey Leigh, MD</au><au>Schwartzman, William, MD</au><au>Dowell, Jonathan E., MD</au><au>Shaverdashvili, Khvaramze, MD</au><au>Villaruz, Liza, MD</au><au>Cass, Amanda, PharmD</au><au>Iams, Wade, MD</au><au>Aisner, Dara, MD, PhD</au><au>Aggarwal, Charu, MD</au><au>Camidge, D. Ross, MD PhD</au><au>Marmarelis, Melina E., MD</au><au>Sun, Lova, MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Characteristics of long-term survivors with EGFR mutant (EGFRm) metastatic non-small cell lung cancer (mNSCLC)</atitle><jtitle>JTO clinical and research reports</jtitle><date>2024</date><risdate>2024</risdate><spage>100669</spage><epage>100669</epage><pages>100669-100669</pages><issn>2666-3643</issn><eissn>2666-3643</eissn><abstract><![CDATA[AbstractIntroductionCharacteristics of long-term survivors in EGFRm NSCLC are not fully understood. This retrospective analysis evaluated a multi-institution cohort of patients with EGFRm NSCLC treated in the pre-osimertinib era and sought to describe characteristics of long-term survivors. MethodsClinical characteristics and outcomes were abstracted from the electronic medical records of patients with EGFRm mNSCLC who started first-line therapy before 2015. Demographics and comutations were compared between ≥5 year survivors and <5 year survivors. Multivariable Cox PH and logistic regression models were used to evaluate factors associated with survival and the odds of death within 5 years, respectively. Results133 patients were ≥5-year survivors; 127 were <5-year survivors. Burden of pathogenic comutations including TP53 and PIK3CA was similar between ≥5-year survivors and <5-year survivors. Receipt of first-line chemotherapy rather than EGFR-TKI was similar between the groups (22% of <5-year vs 31% of ≥5-year). Baseline brain metastasis and history of smoking were associated with higher odds of death within 5 years (OR=2.16, p=0.029 and OR=1.90, p=0.046, respectively). Among patients without baseline brain metastases, cumulative incidence of brain metastases at 5 years was 42.3%. Both baseline and post-baseline brain metastasis were associated with worse OS compared to no brain metastasis (HR=3.26, p<0.001 and HR=4.99, p<0.001, respectively). ConclusionsWithin patients treated for EGFRm mNSCLC prior to 2015, absence of brain metastasis and nonsmoking status were predictive of 5-year survival. Our findings help to define a subset of patients with EGFRm NSCLC with excellent survival outcomes who may not require intensification of initial therapy.]]></abstract><doi>10.1016/j.jtocrr.2024.100669</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2666-3643
ispartof JTO clinical and research reports, 2024, p.100669-100669
issn 2666-3643
2666-3643
language eng
recordid cdi_elsevier_clinicalkeyesjournals_1_s2_0_S2666364324000390
source ScienceDirect; Open Access: PubMed Central
subjects Hematology, Oncology, and Palliative Medicine
title Characteristics of long-term survivors with EGFR mutant (EGFRm) metastatic non-small cell lung cancer (mNSCLC)
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-27T09%3A56%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Characteristics%20of%20long-term%20survivors%20with%20EGFR%20mutant%20(EGFRm)%20metastatic%20non-small%20cell%20lung%20cancer%20(mNSCLC)&rft.jtitle=JTO%20clinical%20and%20research%20reports&rft.au=Tompkins,%20William,%20MD&rft.date=2024&rft.spage=100669&rft.epage=100669&rft.pages=100669-100669&rft.issn=2666-3643&rft.eissn=2666-3643&rft_id=info:doi/10.1016/j.jtocrr.2024.100669&rft_dat=%3Celsevier%3E1_s2_0_S2666364324000390%3C/elsevier%3E%3Cgrp_id%3Ecdi_FETCH-elsevier_clinicalkeyesjournals_1_s2_0_S26663643240003903%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true